[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-350574-en":59,"doc-seo-350574-105":100},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":72,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":73,"language":74,"language_code":75,"site_id":76,"html_lang":75,"table_of_contents":77,"faqs":78,"seo_title":79,"seo_description":66,"update_tm":80,"read_time":81,"preview_page_count":19,"preview_urls":82},350574,24464137899374,"Blitz","https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Lysosomal vulnerability as a therapeutic target in thyroid cancer using fucoidan nanoparticles","Thyroid cancer is a frequent malignancy with aggressive subsets facing limited effective therapies. Fucoidan, a sulfated polysaccharide with anticancer activity of unclear mechanism, was evaluated using fucoidan nanoaggregates (NFU) in tumor (SW1736) and non-tumorigenic thyroid cells (Nthy-ori 3.1). NFU showed ~187 nm size and inhibited SW1736 viability selectively, while sparing non-tumorigenic cells. NFU provoked tumor-selective lysosomal enlargement and perturbed LAMP-1–positive compartments, aligning with constitutive cathepsin D maturation and heightened sensitivity to lysosomal stress.","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLysosomal vulnerability as a therapeutic target in thyroid cancer using fucoidan nanoparticles  \nMarilena Celano1,3􀀍, Agnese Gagliardi1,3, Raffaella Gallo2, Elena Giuliano1, Diego Russo1, Donato Cosco1􀀍 & Giuseppe Fiume2􀀍  \nThyroid cancer represents the ninth most common malignancy worldwide, and a subset of cases exhibits aggressive behaviour with limited therapeutic options. Fucoidan, a sulphated polysaccharide, has demonstrated anticancer activity with an undefined mechanism. Here, we investigated the biological effects offucoidan (FU) and fucoidan nanoaggregates (NFU) in both thyroid cancer (SW1736) and non-tumorigenic thyroid cells (Nthy-ori 3.1) . NFU showed a mean diameter of ~ 187 nm, a low polydispersity (~ 0.2) and a negative Zeta potential. NFU significantly reduced SW1736 cell viability, reaching ~ 60% inhibition at 0.01 mg/mL and ~ 80% at 0.1 mg/mL after 72 h, while sparing non-tumorigenic cells. Mechanistically, NFU induced marked lysosomal enlargement selectively in tumor cells and localized predominantly within LAMP-1–positive compartments. Consistently, tumor cells showed constitutive Cathepsin D maturation and enhanced sensitivity to NFU-induced lysosomal perturbation. Collectively, these findings identify lysosomes as a primary intracellular target offucoidan-based nanosystems and reveal a tumor-selective vulnerability to NFU-mediated lysosomal stress. This study provides the first quantitative evidence of lysosomal targeting by fucoidan nanoparticles in thyroid cancer cells and supports NFU as a promising lysosome-directed nanotherapeutic strategy for aggressive thyroid malignancies.  \nKeywords Colloids, Fucoidan, Human thyroid carcinoma, Lysosomes, Cathepsin D  \nThyroid cancer represents the most common endocrine malignancy, with a rising incidence globally over recent decades. While differentiated thyroid carcinomas generally have favorable prognoses, undifferentiated subtypes such as anaplastic thyroid carcinoma (ATC) remain highly aggressive and resistant to conventional therapies based on surgery and radioiodine, underscoring the need for novel targeted treatment strategies1. The genetic and epigenetic characterization of thyroid tumors exerted an important role on the identification of novel molecular targets and currently, several combination of checkpoint inhibitors with other treatment approaches are currently being investigated. An innovative approach as the adoptive immunotherapy as the Anti-CD19 chimeric antigen receptor T cell (CAR-T) and has recently even been tested against preclinical models of thyroid cancer2. Unfortunately at present, none of the available treatments are satisfactorily effective for ATC. Clinical trial results indicate that the current targeted compounds are able to prolong progression-free survival rather than offer a decisive cure, because both the presence of intolerable adverse events and the occurrence of secondary resistance make this approach3–5. Therefore, the search for alternative therapies has increasingly focused on naturally derived bioactive compounds with selective anticancer properties and favorable safety profiles. In recent years, the exploration of bioactive molecules derived from natural sources as macroalgae rich in polysaccharides (e.g., fucoidans and alginates), polyphenols (e.g., phlorotannins), and terpenoids, has gained particular interest6. Fucoidan (FU) is a sulfated polysaccharide mainly derived from brown algae such as Fucus vesiculosus, Undaria pinnatifida, and Laminaria japonica, and has attracted growing interest due to its broad biological activities, including anticoagulant, antioxidant, immunomodulatory, and particularly antitumor effects6–10.  \nExtensive in vitro and in vivo studies have demonstrated that FU inhibits tumor cell proliferation and promotes apoptosis in multiple cancer types, including leukemia, breast, liver, and colon cancers11–16. The mechan","cbCaijEKSlPOte7p","https://ap.wps.com/l/cbCaijEKSlPOte7p","pdf",2002030,13,11,"English","en",105,"# Introduction\n# Fucoidan and anticancer background\n# NFU characterization and cytotoxic effects\n# Lysosomal mechanism and cathepsin D involvement\n# Therapeutic implications","[{\"question\":\"What problem does the study address in thyroid cancer treatment?\",\"answer\":\"It targets the limited therapeutic options for aggressive thyroid cancer subtypes and the need for novel targeted strategies.\"},{\"question\":\"How do fucoidan nanoaggregates (NFU) affect thyroid cancer cell viability?\",\"answer\":\"NFU significantly reduces SW1736 viability in a dose-dependent manner over 72 hours while sparing non-tumorigenic thyroid cells.\"},{\"question\":\"What cellular mechanism explains NFU’s tumor-selective effect?\",\"answer\":\"NFU induces marked lysosomal enlargement selectively in tumor cells and localizes predominantly in LAMP-1–positive compartments, linked to enhanced sensitivity involving cathepsin D maturation.\"}]","Lysosomal vulnerability as a therapeutic target in thyroid cancer using fucoidan nanoparticles | PDF",1790089672,28,[83,87,91,96],{"page_no":8,"url":84,"width":85,"height":86},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25155baf542cd7d69be71466382b7de5.webp",983,1291,{"page_no":14,"url":88,"width":89,"height":90},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9359ad6bd028f78175b4214fafdf0c8.webp",982,1290,{"page_no":92,"url":93,"width":94,"height":95},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78f0c7838db39ba98f428c189ef531bd.webp",981,1289,{"page_no":19,"url":97,"width":98,"height":99},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51b306b2330bdc78714dd81e7a712ea1.webp",980,1287,{"code":4,"msg":101,"data":102},"ok",{"site_id":76,"language":75,"slug":103,"title":65,"keywords":104,"description":66,"schema_data":105,"social_meta":158,"head_meta":160,"extra_data":162,"updated_unix":163},"lysosomal-vulnerability-as-a-therapeutic-target-in-thyroid-cancer-using-fucoidan-nanoparticles","",{"@graph":106,"@context":157},[107,120,140],{"@type":108,"itemListElement":109},"BreadcrumbList",[110,114,116,118],{"item":111,"name":112,"@type":113,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":115,"name":9,"@type":113,"position":14},"https://docshare.wps.com/document/",{"item":117,"name":40,"@type":113,"position":92},"https://docshare.wps.com/document/research-report/",{"item":119,"name":65,"@type":113,"position":19},"https://docshare.wps.com/document/lysosomal-vulnerability-as-a-therapeutic-target-in-thyroid-cancer-using-fucoidan-nanoparticles/350574/",{"url":119,"name":65,"@type":121,"image":122,"author":127,"headline":65,"publisher":129,"fileFormat":132,"inLanguage":75,"description":66,"dateModified":133,"datePublished":134,"encodingFormat":132,"isAccessibleForFree":135,"interactionStatistic":136},"DigitalDocument",{"url":123,"@type":124,"width":125,"height":126},"https://docshare.wps.com/thumbnails/lysosomal-vulnerability-as-a-therapeutic-target-in-thyroid-cancer-using-fucoidan-nanoparticles/350574.png","ImageObject",300,407,{"name":63,"@type":128},"Person",{"url":111,"name":130,"@type":131},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":137,"interactionType":138,"userInteractionCount":72},"InteractionCounter",{"@type":139},"ViewAction",{"@type":141,"mainEntity":142},"FAQPage",[143,149,153],{"name":144,"@type":145,"acceptedAnswer":146},"What problem does the study address in thyroid cancer treatment?","Question",{"text":147,"@type":148},"It targets the limited therapeutic options for aggressive thyroid cancer subtypes and the need for novel targeted strategies.","Answer",{"name":150,"@type":145,"acceptedAnswer":151},"How do fucoidan nanoaggregates (NFU) affect thyroid cancer cell viability?",{"text":152,"@type":148},"NFU significantly reduces SW1736 viability in a dose-dependent manner over 72 hours while sparing non-tumorigenic thyroid cells.",{"name":154,"@type":145,"acceptedAnswer":155},"What cellular mechanism explains NFU’s tumor-selective effect?",{"text":156,"@type":148},"NFU induces marked lysosomal enlargement selectively in tumor cells and localizes predominantly in LAMP-1–positive compartments, linked to enhanced sensitivity involving cathepsin D maturation.","https://schema.org",{"og:url":119,"og:type":159,"og:title":65,"og:site_name":130,"og:description":66},"article",{"robots":161,"canonical":119},"index,follow",{"doc_id":61,"site_id":76},1790175805]